Quick Answer
Twist Bioscience Corp reported Stockholders Equity of $472.96 million for the year ending 2025.
- Twist Bioscience Corp showed an increase of +0.1% in Stockholders Equity from 2024 to 2025.
- This data is from Twist Bioscience Corp's annual report (Form 10-K), filed with the SEC on November 17, 2025.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: -$149.70 million | Q1 2018: -$165.72 million | Q2 2018: -$182.76 million | Q4 2018: $138.60 million | Q1 2019: $115.48 million | Q2 2019: $176.00 million | Q4 2019: $103.08 million | Q1 2020: $264.20 million | Q2 2020: $348.95 million | Q4 2020: $637.95 million | Q1 2021: $614.18 million | Q2 2021: $610.45 million | Q4 2021: $626.18 million | Q1 2022: $863.36 million | Q2 2022: $820.68 million | Q4 2022: $746.33 million | Q1 2023: $703.93 million | Q2 2023: $657.55 million | Q4 2023: $590.04 million | Q1 2024: $560.13 million | Q2 2024: $491.14 million | Q3 2024: $472.69 million | Q4 2024: $455.94 million | Q1 2025: $440.11 million | Q2 2025: $478.20 million | Q3 2025: $472.96 million | Q4 2025: $456.10 million.
- Over the full 10 years of available data (2016 to 2025), Twist Bioscience Corp's Stockholders Equity has grown by 717.3%.
- Historical annual values: Fiscal year 2025: $472.96 million | Fiscal year 2024: $472.69 million | Fiscal year 2023: $623.43 million | Fiscal year 2022: $789.39 million | Fiscal year 2021: $580.82 million | Fiscal year 2020: $336.26 million | Fiscal year 2019: $152.08 million | Fiscal year 2018: -$201.42 million | Fiscal year 2017: -$133.36 million | Fiscal year 2016: -$76.61 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: